Sensus Healthcare, Inc. (SRTS) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 233.33%. A quarter ago, it was expected that this company would post a loss of $0.04 per share when it actually produced earnings of $0.14, delivering a surprise of 450%.Over the last four quarters, the company ...

财务业绩 - 公司第二季度收入同比增长104%至920万美元[3] - 公司第二季度净利润为160万美元，每股0.10美元[13] - 公司第二季度调整后EBITDA为210万美元[14] - 公司上半年收入同比增长152%至2000万美元[16] - 公司上半年净利润为390万美元，每股0.24美元[22] - 公司上半年调整后EBITDA为510万美元[22] - 公司2024年第二季度收入为9,239千美元，同比增长104%[32] - 2024年上半年收入为19,902千美元，同比增长150%[32] - 2024年第二季度毛利为5,423千美元，毛利率为58.7%[32] - 2024年上半年毛利为12,085千美元，毛利率为60.7%[32] 现金流及资产负债 - 2024年6月30日现金及现金等价物余额为18,972千美元[34] - 2024年6月30日应收账款净额为18,293千美元[34] - 2024年6月30日存货为12,769千美元[34] - 2024年6月30日总资产为58,163千美元[34] - 2024年6月30日总负债为5,262千美元[34] - 2024年6月30日股东权益为52,901千美元[34] 业务发展 - 公司已与15家客户签订"公平交易协议"以获取经常性收入[5] - 公司持续增加库存以应对预期的客户需求[15] - 公司正在亚洲市场拓展,第二季度向中国和台湾发货3台设备[6] - 公司目标是将SRT技术推广为治疗非黑色素瘤皮肤癌和瘢痕疙瘩的标准治疗方式[6]

The stock market bounced back on Tuesday following Monday’s market-wide selloff. Stocks were due for a pullback following the huge first-half rally, and the recent wave of selling has helped cool off the market.Despite the possibility of more near-term selling and volatility, the last several years highlight why investors must attempt to stay exposed to the stock market at all times. Investors who want to buy stocks in August and the rest of the summer might consider searching for stocks gaining more attent ...

The most recent trading session ended with Sensus Healthcare, Inc. (SRTS) standing at $6.25, reflecting a -1.88% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's daily loss of 1.37%. Meanwhile, the Dow experienced a drop of 1.21%, and the technology-dominated Nasdaq saw a decrease of 2.3%.Coming into today, shares of the company had gained 25.64% in the past month. In that same time, the Medical sector gained 0.74%, while the S&P 500 gained 1.11%.The upcoming ea ...

BOCA RATON, Fla., July 25, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Par ...

文章核心观点 - 公司预计将在2024年第二季度报告中实现营收和利润同比增长 [1][2] - 公司的实际业绩表现是影响其股价短期走势的关键因素 [2][3] - 分析师对公司未来盈利的预期将决定股价的持续走势 [3] 公司业绩分析 - 公司预计将在2024年第二季度实现每股收益0.03美元,同比增长250% [4] - 预计营收将达到7百万美元,同比增长54.5% [4] - 分析师近30天内未对预测数据进行调整,反映了他们对公司业绩的整体预期 [5][6] 业绩超预期分析 - 公司最新业绩预测值高于共识预期,Earnings ESP为+20%,表明可能会超预期 [12] - 公司目前评级为Zacks Rank 2,这种组合通常预示着业绩会超预期 [12] - 公司过去4个季度中有3次超出了共识预期 [14] 行业对比 - 同行业公司Waters预计2024年第二季度每股收益为2.55美元,同比下降8.9% [18] - Waters的Earnings ESP为-0.57%,加上Zacks Rank 4,预示其难以超预期 [19][20]

Sensus Healthcare, Inc. (SRTS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The powe ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, ...

Sensus Healthcare, Inc. (SRTS) closed the most recent trading day at $4.87, moving -1.81% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.09% for the day. Meanwhile, the Dow experienced a drop of 0.1%, and the technology-dominated Nasdaq saw an increase of 0.16%. The company's stock has dropped by 18.69% in the past month, falling short of the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83%. The investment community will be closely monitorin ...

The most recent trading session ended with Sensus Healthcare, Inc. (SRTS) standing at $5.22, reflecting a -1.51% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.77% gain on the day. Elsewhere, the Dow saw an upswing of 0.49%, while the tech-heavy Nasdaq appreciated by 0.95%. Shares of the company have depreciated by 10.62% over the course of the past month, underperforming the Medical sector's gain of 1.49% and the S&P 500's gain of 3.71%. Analysts and investors alike will ...